AstraZeneca PLC's (AZN) 澳洲幸运5开奖号码历史查询:American depositary receipts (ADRs) fell more than 4% Thursday after the drug maker reported its profit was hurt by falling demand for CO💖VID-19 treatments.

The Anglo-Swedish pharmaceutical firm reported fourth-quarter core earnings per share (EPS) of $1.45, short of forecasts. Revenue rose 7% to $12.02 billion, basically in line with 澳洲幸运5开奖号码历史查询:analysts' estimates.

For the full year, core EPS was $7.26, with revenue up 3% to $45.81 billion. The company nꦇoted that revenue was negatively affected by slumping sales of COVID-19 vaccines and immune therapies (V&I), which reduced the total b♕y $3.74 billion.

Fourth-quarter V&I revenue plunged 64% to $413 million 澳洲幸运5开奖号码历史查询:year-on-year (YOY) following “historic contracts” in 2022 for its Vaxzevria shot and monoclonal antibodies (mAbs) treatments. Sales of its “Other Medicines” category slipped 33% as its Nexium acid reflux pill faced generic competition in Japan.

Chief Executive Officer (CEO) Pascal Soriot remained optimistic, saying that the firm’s “differentiated and growing portfolio of approved medicines, global reach and rich R&D pipeline give us confidence that we will cont💫inue to deliver industry-leading growth.”

AstraZeneca sees full-year core EPS and revenue increasing by a low-double-digit to a low-teens percentage at 澳洲幸运5开奖号码历史查询:constant exchange rates.

AstraZeneca ADRs were down 4.4% at $63.62 Thursday at around 1:45 p.m. ET. The stock, which fell as low as $61.70 earlier in the session, reached its lowest level since Octob𓆉er 2022.